GE Healthcare Launches Biacore T200 for Comprehensive Characterization of Biomolecular Interactions

16 Nov 2010
Sarah Sarah
Marketing / Sales

Product news

GE Healthcare announces the launch of Biacore™ T200, designed to deliver exceptional sensitivity in the measurement of high quality kinetic, affinity, concentration, specificity, and thermodynamic interaction data, in real time. The system builds upon the success of the widely adopted Biacore T100.

The performance, versatility and sensitivity of Biacore T200 enables analysis of interactions involving the smallest, low molecular weight compounds, interactions of rare targets, and facilitates the analysis of interactions involving G protein-coupled receptors. The outstanding sensitivity of the system also allows antigen immobilization levels so low that interactions with antibody in solution can be analysed, without avidity effects, thus adding flexibility to assay design. In addition, the system expands the range of kinetic parameters that can be studied with the highest precision and confidence, from the fastest on-rates to the slowest off-rates.

Guided workflows and the ability to analyse up to 384 samples in unattended runs facilitates rapid data acquisition for a large range of biomolecular interaction studies, including defining potential drug targets and diagnostic markers, and time- and cost-efficient concentration analysis in vaccine development. Calibration-free concentration analysis enables highly reproducible, precise measurement of active protein concentration, whether or not a standard is available.

Dr. Johan Weigelt, SGC, Karolinska Institutet, commented: “The high sensitivity and information-rich data of Biacore T200 allowed us to assess inhibitor selectivity and identify weak binders not possible with our alternative technology. The findings are of great value as a starting point for development of selective inhibitors of novel PARP enzymes.”

Biacore T200 software also provides dedicated support for confident immunogenicity testing, for detection and characterization of anti-drug antibodies during preclinical and clinical development. The optional GxP Package enables Biacore T200 to integrate seamlessly into GxP-regulated workflows.

Links

Tags

ProteomicsProteomics is the systemic bioinformatics study of proteins and amino acids, including their structure, size, function and identification. Tools used in proteomics include chromatography, blotting and gels, protein arrays, mass spectrometry and ELISA and associated analysis software. Analyzers and proteomic systems should be sensitive, high resolution, fast and may be automated for high-throughput.Process ChemistryProcess chemistry is an important stage of drug development for scaling-up drug production or chemical synthesis reactions. It is useful for optimizing economical and efficient drug production. Process chemistry uses reactors and pump systems as well as reagents, standards and buffers.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.
GE Healthcare Launches Biacore T200 for Comprehensive Characterization of Biomolecular Interactions